1. Home
  2. NPCT vs PROF Comparison

NPCT vs PROF Comparison

Compare NPCT & PROF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuveen Core Plus Impact Fund of Beneficial Interest

NPCT

Nuveen Core Plus Impact Fund of Beneficial Interest

HOLD

Current Price

$10.28

Market Cap

294.2M

Sector

Finance

ML Signal

HOLD

Logo Profound Medical Corp.

PROF

Profound Medical Corp.

HOLD

Current Price

$6.49

Market Cap

238.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NPCT
PROF
Founded
2020
N/A
Country
United States
Canada
Employees
N/A
N/A
Industry
Investment Managers
Medical/Dental Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
294.2M
238.1M
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
NPCT
PROF
Price
$10.28
$6.49
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$12.00
AVG Volume (30 Days)
145.8K
256.3K
Earning Date
01-01-0001
05-07-2026
Dividend Yield
9.82%
N/A
EPS Growth
N/A
25.89
EPS
N/A
1.41
Revenue
N/A
$16,098,000.00
Revenue This Year
N/A
$92.40
Revenue Next Year
N/A
$64.10
P/E Ratio
N/A
$4.52
Revenue Growth
N/A
50.73
52 Week Low
$9.80
$3.92
52 Week High
$11.31
$8.95

Technical Indicators

Market Signals
Indicator
NPCT
PROF
Relative Strength Index (RSI) 56.63 53.98
Support Level $10.16 $5.75
Resistance Level $10.32 $7.08
Average True Range (ATR) 0.15 0.45
MACD 0.05 0.14
Stochastic Oscillator 72.86 78.07

Price Performance

Historical Comparison
NPCT
PROF

About NPCT Nuveen Core Plus Impact Fund of Beneficial Interest

Nuveen Core Plus Impact Fund is an organized, diversified, closed-end management investment company. The Fund's investment objective is to seek total return through high current income and capital appreciation, while giving special consideration to certain impact and environmental, social and governance criteria.

About PROF Profound Medical Corp.

Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.

Share on Social Networks: